Praxis Precision Medicines Advances Two CNS Programs with Positive FDA Meeting and Phase 2 Results
核心洞察
Praxis Precision Medicines completed a positive pre-NDA meeting with the FDA for ulixacaltamide, an essential tremor (搜索) treatment, with plans to file the company's first NDA in early 2026.
The company reported positive Phase 2 results for relutrigine in developmental and epileptic encephalopathies (搜索), showing robust improvement in motor seizures with a well-tolerated safety profile.
Both programs represent significant milestones for Praxis's CNS portfolio, targeting neurological disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines announced significant progress across two key central nervous system programs, completing a positive pre-new drug application meeting with the FDA for its essential tremor (搜索) treatment ulixacaltamide and reporting encouraging Phase 2 results for relutrigine in epileptic encephalopathies.
The clinical-stage biopharmaceutical company expects to file its first NDA for ulixacaltamide in early 2026 following the successful regulatory interaction. Ulixacaltamide represents a differentiated approach to treating essential tremor (搜索) as a highly selective small molecule inhibitor of T-type calcium channels (搜索), designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.
Positive Phase 2 Results for Epilepsy Treatment
Praxis also reported positive results from the first cohort of a Phase 2 study evaluating relutrigine for patients with certain forms of developmental and epileptic encephalopathies (搜索). The data demonstrated a well-tolerated safety profile with robust improvement in motor seizures among a heavily pre-treated patient population.
The FDA has confirmed a meeting to review the relutrigine data, with Praxis planning to determine the timeline for filing an NDA following these regulatory discussions. The company will present the complete results from the relutrigine study at the American Epilepsy (搜索) Society Annual Meeting on Saturday.
Strategic CNS Portfolio Development
Both programs exemplify Praxis's approach to translating insights from genetic epilepsies into therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Ulixacaltamide serves as the most advanced program within the company's proprietary Cerebrum small molecule platform.
Praxis has established a diversified, multimodal CNS portfolio spanning movement disorders and epilepsy (搜索), with four clinical-stage product candidates across its Cerebrum small molecule platform and Solidus antisense oligonucleotide platform. The company leverages understanding of shared biological targets and circuits in the brain to develop treatments for both rare and more prevalent neurological disorders.